Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.

Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L.

Blood. 2012 Mar 8;119(10):2228-33. doi: 10.1182/blood-2011-08-376012. Epub 2012 Jan 5.

2.

Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.

Hoffmann C, Schmid H, Müller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski M, Horst HA, Reuter S, Vogel M, Jäger H, Bogner J, Arasteh K.

Blood. 2011 Sep 29;118(13):3499-503. doi: 10.1182/blood-2011-02-333633. Epub 2011 Jul 21.

3.

High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.

Oksenhendler E, Boulanger E, Galicier L, Du MQ, Dupin N, Diss TC, Hamoudi R, Daniel MT, Agbalika F, Boshoff C, Clauvel JP, Isaacson PG, Meignin V.

Blood. 2002 Apr 1;99(7):2331-6.

4.

Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi.

Gopal S, Liomba NG, Montgomery ND, Moses A, Kaimila B, Nyasosela R, Chikasema M, Dhungel BM, Kampani C, Sanders MK, Krysiak R, Dittmer DP, Fedoriw Y.

J Int AIDS Soc. 2015 Aug 3;18:20122. doi: 10.7448/IAS.18.1.20122. eCollection 2015.

5.

Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease.

Casquero A, Barroso A, Fernández Guerrero ML, Górgolas M.

Ann Hematol. 2006 Mar;85(3):185-7. Epub 2005 Dec 10.

PMID:
16341862
6.

Brief communication: rituximab in HIV-associated multicentric Castleman disease.

Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P.

Ann Intern Med. 2007 Dec 18;147(12):836-9.

PMID:
18087054
7.

Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.

Uldrick TS, Polizzotto MN, Aleman K, Wyvill KM, Marshall V, Whitby D, Wang V, Pittaluga S, O'Mahony D, Steinberg SM, Little RF, Yarchoan R.

Blood. 2014 Dec 4;124(24):3544-52. doi: 10.1182/blood-2014-07-586800. Epub 2014 Oct 20.

8.

Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease.

Neuville S, Agbalika F, Rabian C, Brière J, Molina JM.

Am J Hematol. 2005 Aug;79(4):337-9.

9.

Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.

Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E.

J Clin Oncol. 2007 Aug 1;25(22):3350-6.

10.

How I treat HIV-associated multicentric Castleman disease.

Bower M.

Blood. 2010 Nov 25;116(22):4415-21. doi: 10.1182/blood-2010-07-290213. Epub 2010 Aug 5.

11.

Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.

Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J; Caelyx/Kaposi's Sarcoma Spanish Group.

Clin Infect Dis. 2008 Aug 1;47(3):410-7. doi: 10.1086/589865.

12.

Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.

Reid E, Nooka A, Blackmon J, Lechowicz MJ.

Curr Drug Deliv. 2012 Jan;9(1):41-51. Review.

PMID:
22023215
13.

HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.

Nicoli P, Familiari U, Bosa M, Allice T, Mete F, Morotti A, Cilloni D, Saglio G, Guerrasio A.

Int J Hematol. 2009 Oct;90(3):392-6. doi: 10.1007/s12185-009-0418-y. Epub 2009 Sep 12.

PMID:
19756920
14.

Multicentric Castleman's disease in HIV infection: a systematic review of the literature.

Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A.

AIDS Rev. 2008 Jan-Mar;10(1):25-35. Review.

PMID:
18385778
15.

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.

Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, Kinoshita T, Uike N, Ogura M, Nawano S, Mori S, Ohashi Y; IDEC-C2B8 Study Group.

Cancer Sci. 2011 Sep;102(9):1698-705. doi: 10.1111/j.1349-7006.2011.02001.x. Epub 2011 Jul 8.

16.

The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease.

Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M.

Ann Oncol. 2009 Apr;20(4):775-9. doi: 10.1093/annonc/mdn697. Epub 2009 Jan 29.

17.

High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi's sarcoma.

Ridolfo AL, Santambrogio S, Mainini F, Vago L, Gervasoni C, Gori A, Parravicini C, Monforte A, Galli M.

AIDS. 1996 Feb;10(2):181-5.

PMID:
8838706
18.

Rituximab therapy for HIV-associated Castleman disease.

Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N.

Blood. 2003 Oct 15;102(8):2786-8. Epub 2003 Jul 3.

19.

What Is the best treatment for HIV-associated multicentric Castleman disease?

Bower M, Dalla Pria A.

Clin Adv Hematol Oncol. 2012 Mar;10(3):207-9. Review. No abstract available.

PMID:
22402432
20.
Items per page

Supplemental Content

Write to the Help Desk